- Home
- » Tags
- » Urtoxazumab
Top View
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- (INN) for Biological and Biotechnological Substances
- Management of Shiga Toxin-Associated Escherichia Coli-Induced Haemolytic Uraemic Syndrome: Randomized Clinical Trials Are Needed
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Who Expert Committee on Specifications for Pharmaceutical Preparations
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
- Controlling Enterohemorrhagic E. Coli O157: H7 Using Selenium and Rutin Meera Surendran Nair University of Connecticut - Storrs, [email protected]
- Artículo Especial Desarrollo De Un Producto Anti-Toxina Shiga Para La Prevención Del Síndrome Urémico Hemolítico
- Shiga-Toxin E. Coli Hemolytic Uremic Syndrome: Review of Management and Long-Term Outcome
- Assessment of the Evolution of Cancer Treatment Therapies
- Molecular Targets and Strategies to Overcome Antibiotic Resistance
- Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management
- Interaction Between Shiga Toxin and Monoclonal Antibodies: Binding Characteristics and in Vitro Neutralizing Abilities
- Prediction of Clearance of Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins in Children: Application of Allometric Scaling
- Nemorubicin Metabolite and Analog Reagents, Antibody
- Vaccine Monoclonal Antibody-Based Therapies for Microbial Diseases
- Shiga Toxin-Associated Hemolytic Uremic Syndrome: a Narrative Review Adrien Joseph, Aurélie Cointe, Patricia Kurkdjian, Cédric Rafat, Alexandre Hertig
- Impact of the Nature and Size of the Polymeric Backbone on the Ability
- Gm, Ke, Lr, Ls, Mw, Mz, Na, Rw, Sd, Sl, St, Sz, Tz, Ug, Zm, Zw
- Malik Paul.Pdf (4.898Mb)
- Monoclonal Antibodies Targeting Clostridium Difficile Licensed to Merck
- (INN) for Biological and Biotechnological Substances
- Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in Vitro and in Vivo
- Experimental in Vivo Models of Bacterial Shiga Toxin-Associated
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- Q:\Users\Brendac\Pharmaceutical Zeroforzero Initiative FINAL Edited
- Management of Shiga Toxin-Associated Escherichia Coli-Induced Haemolytic Uraemic Syndrome: Randomized Clinical Trials Are Needed
- Assessment of the Evolution of Cancer Treatment Therapies
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Us 2019 / 0127401 A1
- Fighting Bacterial Infections—Future Treatment Optionsଝ
- WHO Drug Information Vol. 18, No. 3, 2004